The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT 2026 | The EBMT recommendations for MRD-guided interventions in patients with AML undergoing alloSCT
Francesco Buccisano, MD, University of Rome Tor Vergata, Rome, Italy, provides insight into the EBMT best-practice recommendations for measurable residual disease (MRD)-guided interventions in patients with acute myeloid leukemia (AML) undergoing allogeneic stem cell transplantation (alloSCT). Dr Buccisano details the use of MRD as a biomarker following AML treatment to guide treatment regimen selection and determine which patients qualify for transplantation. This interview took place at the 52nd Annual Meeting of the EBMT in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We have recently published a consensus about this. It was a panel that combined EBMT experts but also experts from the ELN European Leukemia Net David Working Party and we gave some advice on the use of MRD assessment in relation with the treatment planning. Measurable residual disease is a biomarker of good quality of response after initial frontline treatment in AML...
We have recently published a consensus about this. It was a panel that combined EBMT experts but also experts from the ELN European Leukemia Net David Working Party and we gave some advice on the use of MRD assessment in relation with the treatment planning. Measurable residual disease is a biomarker of good quality of response after initial frontline treatment in AML. So it’s a key biomarker to decide about the intensity of treatment after remission achievement. So MRD is a key tool in this view. This means that patients that are MRD negative can be spared a frontline allogenic stem cell transplant if they belong to the favorable or intermediate risk. Whereas in adverse risk, allogeneic stem cell transplant is suggested regardless of the MRD status, but MRD may indeed be useful, may still be useful in selecting the intensity of conditioning regimen or in prescribing a maintenance treatment after transplant.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Jazz, Menarini, Servier
